Yes, DDD, they included HE in the things they used expenses for. Now the question is...are they paying expenses to train personnel at German hospitals in prep of initiating HE, or are they actually providing the treatment to HE patients, perhaps even collecting payment from some patients. Remember, patients can self-pay and be reembursed by health funds once the deals are completed, and out-of-country patients would self-pay anyway.
So my own thought is that NWBO may already have a nice cashe of money set aside in an an escrow account, waiting to reveal once all pricing negotiations are over, including negotiations in the US, if and when DCVaxL is approved. The filing that allowed them not to report a financial matter some short time ago may have given them the right to withhold that info so as not to interfere with pricing in the US. Let's face it, if they revealed they had money coming in from HE, they would have to report the amount they were charging, and Europe is likely to get the treatment for less than we would in the US. At least, I've read that's the case with new drugs/treatments....we pay the bulk of the development cost.
This is just my thoughts.
Market Data 
Markets 
AI
